Effects of haloperidol metabolites on neurotransmitter uptake and release: Possible role in neurotoxicity and tardive dyskinesia

Brain Research

Volumn 788, Issue 1-2, 1998, Pages 215-222

  Wright, Alesia M ^a   Bempong, Jeffrey ^a   Kirby, Michael L ^a   Barlow, Rebecca L ^a   Bloomquist, Jeffrey R ^a  

^a Neurotoxicol Lab Virginia P   (United States)

Author keywords

Haloperidol pyridinium; Haloperidol tetrahydropyridine; Parkinsonism; Reduced haloperidol pyridinium; Schizophrenia

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DRUG METABOLITE; HALOPERIDOL; HALOPERIDOL PYRIDINIUM; HALOPERIDOL TETRAHYDROPYRIDINE; NEUROTRANSMITTER; PYRIDINIUM DERIVATIVE; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; MOUSE; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NEUROTRANSMITTER UPTAKE; NONHUMAN; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BIOGENIC MONOAMINES; DOPAMINE UPTAKE INHIBITORS; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MICE; NEUROTOXINS; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES;

EID: 0032579840     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01551-5     Document Type: Article

References (23)

1. Avent K., Riker R., Fraser G., Van der Schyf C., Usuki E., Pond S. Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci. 61:1997;2383-2390.
2. +-like neurotoxicity of a pyridinium metabolite of haloperidol. Soc. Neurosci. Abstr. 19:1993;1680.
3. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther. 270:1994;822-830.
4. Bloomquist J., Wright A., Bempong J. In vitro neurotoxicity assessment of oxidative and reductive metabolites of haloperidol. Fundam. Appl. Toxicol., The Toxicologist. 15:1995;69.
5. 3H]mazindol. J. Pharm. Exp. Ther. 253:1990;1206-1214.
6. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
7. A. El-Sobky, Site of action of antischizophrenics, in: W. Winslow, R. Markstein (Eds.), The Neurobiology of Dopamine Systems, Manchester Univ. Press, New York, 1986, pp. 240-251.
8. Eyles D., Avent K., Stedman T., Pond S. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci. 60:1997;529-534.
9. Fang J., Gorrod G.W. Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol. Lett. 59:1991;117-123.
10. Fang J., Yu P. Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology. 121:1995;379-384.
11. +) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology. 121:1995;373-378.
12. Fang J., Zuo D., Yu P. Neurotoxic effect of 4-(4-chlorophenyl)-1-[4-(4′-fluorophenyl)-4-oxobutyl]-pyridinium (HP+), a major metabolite of haloperidol, in the dopaminergic system in vitro and in vivo. Biog. Amines. 12:1996;125-134.
13. Filloux F., Townsend J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 119:1993;79-88.
14. Gerlach J., Casey D. Tardive dyskinesia. Acta Psychiatr. Scand. 77:1988;369-378.
15. Heikkila R.E., Nicklas W.J., Duvoisin R.C. Dopaminergic neurotoxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats. Neurosci. Lett. 59:1985;135-140.
16. Javitch J., D'Amato R., Strittmatter S., Synder S. Parkinsonism-inducing neurotoxin n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite n-methyl-4-phenyl-pyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82:1985;2173-2177.
17. Jonsson G., Nwanae E., Luthman J., Sundstrom E. Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice. Acta Physiol. Scand. 128:1986;187-194.
18. Krueger B.K. Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J. Neurochem. 5:1990;260-267.
19. Marey-Semper I., Gelman M., Levi-Strauss M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopamine neurons from the substantia nigra. Eur. J. Neurosci. 5:1993;1029-1034.
20. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268:1994;380-387.
21. Sirinathsinghji D., Heavens R., McBride C. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions. Brain Res. 443:1988;101-116.
22. Vaccari A., Saba P. The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins. Eur. J. Pharmacol. 292:1995;309-314.
23. Van der Schyf C., Castagnoli K., Usuki E., Fouda H., Rimoldi J., Castagnoli N. Jr. Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem. Res. Toxicol. 7:1994;281-285.